This article was originally published in SRA
Policy on `first' ANDAs for different patents on the same product
You may also be interested in...
Adaptive chief medical officer Lance Baldo talked to Medtech Insight about Adaptive Biotechnologies' plans to detect prior infection using T-cells obtained from blood samples.
Three new directors at Tenax Therapeutics, and a flurry of CMO and CFO appointments.
US firm 180 Life Sciences believes that existing anti-TNF biologics have the potential to address a variety of other conditions in which patients currently have unmet needs. CEO Dr Jim Woody tells Generics Bulletin about how the company is exploring new indications for off-patent biologics.